A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

Two studies found that Zepbound, an anti-obesity medication, may effectively treat obstructive sleep apnea. Drug manufacturer Eli Lilly has applied to the FDA to market Zepbound for obstructive ...

Key Points. GLP-1 agonists have ushered in a new era in anti-obesity medication policy considerations against the backdrop of a continued focus by policymakers on both drug access and pricing.

A new Diabetes drug could be a ‘game changer’ as anti-obesity medication. “This was a well-designed study with unequivocal findings,” Baptiste Leurent, of the London School of Hygiene and ...